• Our Paediatric Neuroinflammatory Disorders program, in collaboration with other site investigators across Canada and internationally, are currently recruiting for several studies under the following areas:
For Multiple Sclerosis

Active Teens with Multiple Sclerosis (ATOMIC) Physical Activity Study

We developed a physical activity intervention using a mobile app tailored for youth with multiple sclerosis (MS). We propose to test the feasibility of implementing this intervention in youth with multiple sclerosis (MS) and to examine the extent to which the intervention can change physical activity levels in this population. We will also evaluate improvement in regional brain volumes, mood, and quality of life in these youth. Learn more here.

You may be eligible for this study if you:

  • are between 11 and 21 years old;
  • have been diagnosed with MS or CIS.

If interested in learning more, please contact Shamashtika Thilagaratnam (416-813-7654 x 328190).

 

Metformin in Children with MS Study

We want to see if we can repair damaged myelin in children with MS using a drug called metformin. Previous research has shown that metformin helps repair myelin in mice and may associate with decreased relapses in adults with MS and metabolic syndromes. Learn more here.

You may be eligible for this study if you:

  • are between 10 and 26 years old;
  • have been diagnosed with MS.

If interested in learning more, please contact Shamashtika Thilagaratnam (416-813-7654 x 328190).

 

Ofatumumab & Siponimod Drug Trial

To demonstrate the non-inferiority of ofatumumab and/or siponimod as compared to fingolimod as assessed by annualized relapse rate (ARR) in the target pediatric MS participants treated for up to 2-years

You may be eligible for this study if you:

  • are between 10 and 18 years old;
  • have been diagnosed with MS.

If interested in learning more, please contact Shamashtika Thilagaratnam (416-813-7654 x 328190).

 

Ocrelizumab Drug Trial

This double-blind, double-dummy study will evaluate the safety and efficacy of ocrelizumab compared with fingolimod in children and adolescents with relapsing-remitting multiple sclerosis ages >= 10 to < 18 years over a duration of at least 96 weeks

You may be eligible for this study if you:

  • are between 10 and 18 years old;
  • have been diagnosed with MS.

If interested in learning more, please contact Shamashtika Thilagaratnam (416-813-7654 x 328190).

For OMAS

OMAS Study

The goal of this study is to investigate eye movement outcomes in relation to brain volume, cognitive function, and disease severity in pediatric OMAS. Learn more here.

You may be eligible for this study if you:

  • are between 6 and 18 years old;
  • have been diagnosed with OMAS.

If interested in learning more, please contact Susana Wu (416-813-7654 x 328575).

For Autoimmune Encephalitis (AE)

Autoimmune Encephalitis (AE) Gene Expression Study

The goal of this study is to identify key molecular and cellular mechanisms of immune responses in childhood autoimmune encephalitides in order to help identify potential disease biomarkers and develop new targeted therapies. Learn more here.

You may be eligible for this study if you:

  • are under 18 years old;
  • have been diagnosed with autoimmune encephalitis.

If interested in learning more, please contact Carmen Yea (416-813-7654 x 308828)

For Acute Flaccid Myelitis/Paralysis (AFM/AFP)

Acute Flaccid Paralysis (AFP) in Canadian Children Study

This study is a national collaborative retrospective evaluation of clinical and MRI outcomes of children presenting with non-polio acute onset flaccid paresis (AFP). Learn more here.

You may be eligible for this study if you:

  • are under 18 years old;
  • have been diagnosed with AFP in the past 30 days.

If interested in learning more, please contact Carmen Yea (416-813-7654 x 308828).

For NMOSD

Eculizumab Drug Trial

To evaluate the efficacy of eculizumab in relapsing pediatric patients with Neuromyelitis Optica Spectrum Disorder (NMOSD).

You may be eligible for this study if you:

  • are between 2 and 18 years old;
  • have been diagnosed with NMOSD

If interested in learning more, please contact Shamashtika Thilagaratnam (416-813-7654 x 328190).

For All Neuroinflammatory Conditions

Social Networks Study

The goal of this study is to understand the effects of COVID-19-related societal changes on health behaviours and mental health outcomes in children and adolescents with neuroinflammatory conditions. Learn more here.

You may be eligible for this study if you:

  • are between 8 and 18 years old;
  • have been diagnosed with a neuroinflammatory disorder.

If interested in learning more, please contact Mina Ly (416-813-7654 x 203796).

 

Neuroinflammatory Patient Registry Study

The purpose of the Registry is to collect information on children with neuroinflammatory disorders for use in research aimed to increase our knowledge of childhood neuroinflammation and to help doctors develop better ways to diagnose and treat children with this rare condition. Learn more here.

You may be eligible for this study if you:

  • are under 18 years old;
  • have been diagnosed with a neuroinflammatory disorder or a suspected neuroinflammatory disorder.
LIFESTYLE OUTCOMES

Check back later for new opportunities!

VISUAL AND NEURO-COGNITIVE OUTCOMES

OMAS Study

The goal of this study is to investigate eye movement outcomes in relation to brain volume, cognitive function, and disease severity in pediatric OMAS. Learn more here.

You may be eligible for this study as a healthy control participant if you:

  • are between 6 and 18 years old;
  • have no significant medical history.

If interested in learning more, please contact Shamashtika Thilagaratnam (416-813-7654 x 328576).

THERAPIES & OUTCOMES IN AUTOIMMUNE ENCEPHALOPATHY

Autoimmune Encephalitis (AE) Gene Expression Study

The goal of this study is to identify key molecular and cellular mechanisms of immune responses in childhood autoimmune encephalitides in order to help identify potential disease biomarkers and develop new targeted therapies. Learn more here.

You may be eligible for this study as a healthy control participant if you:

  • are under 18 years old;
  • have no significant medical history.

If interested in learning more, please contact Carmen Yea (416-813-7654 x 308828) or Olivia Lau (416-813-7654 x 328577).

OTHER STUDIES

Check back later for new opportunities!

Patient Opportunities
For Multiple Sclerosis

Active Teens with Multiple Sclerosis (ATOMIC) Physical Activity Study

We developed a physical activity intervention using a mobile app tailored for youth with multiple sclerosis (MS). We propose to test the feasibility of implementing this intervention in youth with multiple sclerosis (MS) and to examine the extent to which the intervention can change physical activity levels in this population. We will also evaluate improvement in regional brain volumes, mood, and quality of life in these youth. Learn more here.

You may be eligible for this study if you:

  • are between 11 and 21 years old;
  • have been diagnosed with MS or CIS.

If interested in learning more, please contact Shamashtika Thilagaratnam (416-813-7654 x 328190).

 

Metformin in Children with MS Study

We want to see if we can repair damaged myelin in children with MS using a drug called metformin. Previous research has shown that metformin helps repair myelin in mice and may associate with decreased relapses in adults with MS and metabolic syndromes. Learn more here.

You may be eligible for this study if you:

  • are between 10 and 26 years old;
  • have been diagnosed with MS.

If interested in learning more, please contact Shamashtika Thilagaratnam (416-813-7654 x 328190).

 

Ofatumumab & Siponimod Drug Trial

To demonstrate the non-inferiority of ofatumumab and/or siponimod as compared to fingolimod as assessed by annualized relapse rate (ARR) in the target pediatric MS participants treated for up to 2-years

You may be eligible for this study if you:

  • are between 10 and 18 years old;
  • have been diagnosed with MS.

If interested in learning more, please contact Shamashtika Thilagaratnam (416-813-7654 x 328190).

 

Ocrelizumab Drug Trial

This double-blind, double-dummy study will evaluate the safety and efficacy of ocrelizumab compared with fingolimod in children and adolescents with relapsing-remitting multiple sclerosis ages >= 10 to < 18 years over a duration of at least 96 weeks

You may be eligible for this study if you:

  • are between 10 and 18 years old;
  • have been diagnosed with MS.

If interested in learning more, please contact Shamashtika Thilagaratnam (416-813-7654 x 328190).

For OMAS

OMAS Study

The goal of this study is to investigate eye movement outcomes in relation to brain volume, cognitive function, and disease severity in pediatric OMAS. Learn more here.

You may be eligible for this study if you:

  • are between 6 and 18 years old;
  • have been diagnosed with OMAS.

If interested in learning more, please contact Susana Wu (416-813-7654 x 328575).

For Autoimmune Encephalitis (AE)

Autoimmune Encephalitis (AE) Gene Expression Study

The goal of this study is to identify key molecular and cellular mechanisms of immune responses in childhood autoimmune encephalitides in order to help identify potential disease biomarkers and develop new targeted therapies. Learn more here.

You may be eligible for this study if you:

  • are under 18 years old;
  • have been diagnosed with autoimmune encephalitis.

If interested in learning more, please contact Carmen Yea (416-813-7654 x 308828)

For Acute Flaccid Myelitis/Paralysis (AFM/AFP)

Acute Flaccid Paralysis (AFP) in Canadian Children Study

This study is a national collaborative retrospective evaluation of clinical and MRI outcomes of children presenting with non-polio acute onset flaccid paresis (AFP). Learn more here.

You may be eligible for this study if you:

  • are under 18 years old;
  • have been diagnosed with AFP in the past 30 days.

If interested in learning more, please contact Carmen Yea (416-813-7654 x 308828).

For NMOSD

Eculizumab Drug Trial

To evaluate the efficacy of eculizumab in relapsing pediatric patients with Neuromyelitis Optica Spectrum Disorder (NMOSD).

You may be eligible for this study if you:

  • are between 2 and 18 years old;
  • have been diagnosed with NMOSD

If interested in learning more, please contact Shamashtika Thilagaratnam (416-813-7654 x 328190).

For All Neuroinflammatory Conditions

Social Networks Study

The goal of this study is to understand the effects of COVID-19-related societal changes on health behaviours and mental health outcomes in children and adolescents with neuroinflammatory conditions. Learn more here.

You may be eligible for this study if you:

  • are between 8 and 18 years old;
  • have been diagnosed with a neuroinflammatory disorder.

If interested in learning more, please contact Mina Ly (416-813-7654 x 203796).

 

Neuroinflammatory Patient Registry Study

The purpose of the Registry is to collect information on children with neuroinflammatory disorders for use in research aimed to increase our knowledge of childhood neuroinflammation and to help doctors develop better ways to diagnose and treat children with this rare condition. Learn more here.

You may be eligible for this study if you:

  • are under 18 years old;
  • have been diagnosed with a neuroinflammatory disorder or a suspected neuroinflammatory disorder.
Healthy Control Opportunities
LIFESTYLE OUTCOMES

Check back later for new opportunities!

VISUAL AND NEURO-COGNITIVE OUTCOMES

OMAS Study

The goal of this study is to investigate eye movement outcomes in relation to brain volume, cognitive function, and disease severity in pediatric OMAS. Learn more here.

You may be eligible for this study as a healthy control participant if you:

  • are between 6 and 18 years old;
  • have no significant medical history.

If interested in learning more, please contact Shamashtika Thilagaratnam (416-813-7654 x 328576).

THERAPIES & OUTCOMES IN AUTOIMMUNE ENCEPHALOPATHY

Autoimmune Encephalitis (AE) Gene Expression Study

The goal of this study is to identify key molecular and cellular mechanisms of immune responses in childhood autoimmune encephalitides in order to help identify potential disease biomarkers and develop new targeted therapies. Learn more here.

You may be eligible for this study as a healthy control participant if you:

  • are under 18 years old;
  • have no significant medical history.

If interested in learning more, please contact Carmen Yea (416-813-7654 x 308828) or Olivia Lau (416-813-7654 x 328577).

OTHER STUDIES

Check back later for new opportunities!

LEARN MORE ABOUT OUR RESEARCH

To learn more about what our research participants do,
visit the Research Components page.

 

To view our past publications, please click here.